Independent register of U.S. FDA drug recalls · updated Oct 14, 2026
RxRecalls Get alerts

FDA Drug Recalls

11,818 recalls · Class II, newest first

Class II · Moderate risk

Alka-Seltzer Original

Defective Container: Confirmed customer compliant of small holes or cracks in the foil of blister packs.

Terminated Packaging defect Bayer HealthCare Pharmaceuticals, Inc. D-1044-2017
Class II · Moderate risk

hCG Body Shaper

Marketed without an Approved NDA/ANDA; FDA analysis has found the product to be tainted with human chorionic gonadotropin, rendering it an unapproved drug

Terminated Chemical / undeclared Gary Wood D-0677-2017
Class II · Moderate risk

Testosterone Micronized

cGMP Deviations; lack of quality assurance.

Terminated cGMP deviation Qinhuangdao Zizhu Pharmaceutical, Co. NDC 44132-006-06 D-0658-2017
Class II · Moderate risk

Estrone Micronized

cGMP Deviations; lack of quality assurance.

Terminated cGMP deviation Qinhuangdao Zizhu Pharmaceutical, Co. NDC 44132-003-04 D-0657-2017
Class II · Moderate risk

Estriol Micronized

cGMP Deviations; lack of quality assurance.

Terminated cGMP deviation Qinhuangdao Zizhu Pharmaceutical, Co. D-0656-2017
Class II · Moderate risk

Estradiol Micronized Bulk

cGMP Deviations; lack of quality assurance.

Terminated cGMP deviation Qinhuangdao Zizhu Pharmaceutical, Co. NDC 44132-001-01 D-0654-2017
Class II · Moderate risk

Atorvastatin Calcium Tablets

Microbial Contamination of Non-Sterile Products: potential of an elevated bioburden with identification of objectionable organisms.

Terminated Microbial contamination Mylan Institutional, Inc. (d.b.a. UDL Laboratories) NDC 51079-208-20 D-0622-2017
Class II · Moderate risk

Atorvastatin Calcium Tablets

Microbial Contamination of Non-Sterile Products: potential of an elevated bioburden with identification of objectionable organisms.

Terminated Microbial contamination Mylan Pharmaceuticals Inc. NDC 0378-3953-09 D-0621-2017
Class II · Moderate risk

Atorvastatin Calcium Tablets

Microbial Contamination of Non-Sterile Products: potential of an elevated bioburden with identification of objectionable organisms.

Terminated Microbial contamination Mylan Pharmaceuticals Inc. NDC 0378-3952-09 D-0620-2017
Class II · Moderate risk

Atorvastatin Calcium Tablets

Microbial Contamination of Non-Sterile Products: potential of an elevated bioburden with identification of objectionable organisms.

Terminated Microbial contamination Mylan Pharmaceuticals Inc. NDC 0378-3951-09 D-0619-2017
Class II · Moderate risk

Atorvastatin Calcium Tablets

Microbial Contamination of Non-Sterile Products: potential of an elevated bioburden with identification of objectionable organisms.

Terminated Microbial contamination Mylan Pharmaceuticals Inc. NDC 0378-3950-77 D-0618-2017
Class II · Moderate risk

Metronidazole Injection

Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.

Terminated Sterility / contamination Claris Lifesciences Inc NDC 36000-001-24 D-0616-2017
Class II · Moderate risk

Levofloxacin Injection in 5% Dextrose

Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.

Terminated Sterility / contamination Claris Lifesciences Inc NDC 36000-048-24 D-0615-2017
Class II · Moderate risk

Fluconazole Injection

Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.

Terminated Sterility / contamination Claris Lifesciences Inc NDC 36000-003-06 D-0614-2017
Class II · Moderate risk

Ciprofloxacin in Dextrose

Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.

Terminated Sterility / contamination Claris Lifesciences Inc NDC 36000-009-24 D-0613-2017

Recalls by year